Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 406

The plant virus that trains your immune system to kill cancer

A virus from humble black-eyed peas is showing extraordinary promise in the fight against cancer. Unlike other plant viruses, the cowpea mosaic virus (CPMV) can awaken the human immune system and transform it into a cancer-fighting powerhouse, without infecting human cells. By comparing it to a similar, but ineffective, virus, researchers uncovered that CPMV uniquely triggers potent interferons and immune responses, making it a low-cost, plant-grown immunotherapy on the fast track toward clinical trials.

Genomics pioneer George Church earns first retraction for anti-aging gene therapy paper

A paper coauthored by geneticist George Church has been retracted following an internal review at a university where several coauthors are based.

The article appeared in the Proceedings of the National Academy of Sciences in 2022. The work supports an anti-aging gene therapy developed by BioViva, a company for which Church serves as an adviser. The paper’s authors claim cytomegalovirus (CMV) can be a gene therapy vector for a treatment for “aging-associated decline” that can be inhaled or injected monthly.

The work has been cited 41 times, two of which are citations from corrections to the article, according to Clarivate’s Web of Science.

Hackensack Meridian John Theurer Cancer Center Archives

Georgetown Lombardi, Washington’s only National Cancer Institute-designated Comprehensive Cancer Center, serves as the research engine for MedStar Health, Georgetown University’s clinical partner. Georgetown Lombardi is also an NCI-recognized research consortium with John Theurer Cancer Center of Hackensack Meridian Health in Bergen County, New Jersey.

They have a blog with alot of useful cancer information you can share. There is info about them circulating about cancer vaccines and clinical trials. Check em out:

(You can repost their posts or contact them to recieve information from them directly. Lombardi Comprehensive Cancer Center 3,800 Reservoir Rd. NW Washington D.C. 20,057 Phone: 202−444−2223)

AI breakthrough designs peptide drugs to target previously untreatable proteins

A study published in Nature Biotechnology reveals a powerful new use for artificial intelligence: designing small, drug-like molecules that can stick to and break down harmful proteins in the body — even when scientists don’t know what those proteins look like. The breakthrough could lead to new treatments for diseases that have long resisted traditional drug development, including certain cancers, brain disorders, and viral infections.

The study was published on August 13, 2025 by a multi-institutional team of researchers from McMaster University, Duke University, and Cornell University. The AI tool, called PepMLM, is based on an algorithm originally built to understand human language and used in chatbots, but was trained to understand the “language” of proteins.

In 2024, the Nobel Prize in Chemistry was awarded to researchers at Google DeepMind for developing AlphaFold, an AI system that predicts the 3D structure of proteins – a major advance in drug discovery. But many disease-related proteins, including those involved in cancer and neurodegeneration, don’t have stable structures. That’s where PepMLM takes a different approach – instead of relying on structure, the tool uses only the protein’s sequence to design peptide drugs. This makes it possible to target a much broader range of disease proteins, including those that were previously considered “undruggable.”

Cubosome-based method for loading mRNA into exosomes

Exosomes, naturally derived vesicles responsible for intercellular communication, are emerging as next-generation drug delivery systems capable of transporting therapeutics to specific cells. However, their tightly packed, cholesterol-rich membranes make it extremely difficult to encapsulate large molecules such as mRNA or proteins.

Conventional approaches have relied on techniques like electroporation or chemical treatment, which often damage both the drugs and exosomes, reduce delivery efficiency, and require complex purification steps—all of which pose significant barriers to commercialization.

The team utilized a lipid-based nanoparticle known as a “cubosome,” which mimics the fusion structure of cell membranes and naturally fuses with exosomes. By mixing cubosomes carrying mRNA with exosomes at room temperature for just 10 minutes, the researchers achieved efficient fusion and confirmed that the mRNA was successfully loaded into the exosomes. Analysis showed that over 98% of the mRNA was encapsulated, while the structural integrity and biological function of the exosomes were preserved.

Furthermore, the engineered exosomes demonstrated the ability to cross the blood-brain barrier, one of the most difficult hurdles in drug delivery. Notably, the team observed a “homing” effect, where exosomes return to the type of cell they originated from, enabling targeted drug delivery to diseased tissues.

/* */